Who is sponsoring NCT03566446?

NCT03566446 is sponsored by Inge Marie Svane.

What drugs are being tested in NCT03566446?

Interventions in NCT03566446: CALRLong36 peptide.

What condition does NCT03566446 study?

NCT03566446 studies Myeloproliferative Neoplasm, Unclassifiable, Essential Thrombocythemia, Myelofibrosis.

Is NCT03566446 still recruiting?

NCT03566446 is currently completed. Last updated 13 July 2023.

Last reviewed 2023-07-13 · How we verify

NCT03566446

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

CALR Exon 9 Mutant Peptide Vaccine to Patients With CALR-mutant Myeloproliferative Neoplasms

Completed Phase 1 Last updated 13 July 2023

What this trial tests

Phase 1 trial testing CALRLong36 peptide in Myeloproliferative Neoplasm, Unclassifiable in 10 participants. Completed in 30 April 2021.

Timeline

20 June 2018

Primary endpoint
20 February 2020

30 April 2021

Quick facts

Lead sponsor	Inge Marie Svane
Phase	Phase 1
Status	Completed
Study type	INTERVENTIONAL
Allocation	na
Design	single group
Masking	none
Primary purpose	treatment
Enrollment	10
Start date	20 June 2018
Primary completion	20 February 2020
Estimated completion	30 April 2021
Sites	1 location across Denmark

Drugs / interventions tested

CALRLong36 peptide — full drug profile →

Conditions studied

Myeloproliferative Neoplasm, Unclassifiable — all drugs for Myeloproliferative Neoplasm, Unclassifiable →
Essential Thrombocythemia — all drugs for Essential Thrombocythemia →
Myelofibrosis — all drugs for Myelofibrosis →

Sponsor

Inge Marie Svane — full company profile →

Who can join

18 and older, any sex, with Myeloproliferative Neoplasm, Unclassifiable or Essential Thrombocythemia. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

A phase-I-first in man study in patients with calreticulin(CALR)-mutant MPN by vaccinating with exon 9 mutated peptide with the adjuvant Montanide ISA-51 to monitor safety and toxicity and the immunological response to vaccination.

Publications & conference data

8 peer-reviewed publications reference this trial (live from Europe PMC):

Calreticulin and cancer.
Fucikova J, Spisek R, Kroemer G, Galluzzi L. · · 2021 · cited 322× · PMID 32733014 · DOI 10.1038/s41422-020-0383-9
Mutant calreticulin in myeloproliferative neoplasms.
How J, Hobbs GS, Mullally A. · · 2019 · cited 64× · PMID 31562135 · DOI 10.1182/blood.2019000622
Therapeutic Cancer Vaccination With a Peptide Derived From the Calreticulin Exon 9 Mutations Induces Strong Cellular Immune Responses in Patients With <i>CALR</i>-Mutant Chronic Myeloproliferative Neoplasms.
Handlos Grauslund J, Holmström MO, Jørgensen NG, Klausen U, et al · · 2021 · cited 38× · PMID 33718228 · DOI 10.3389/fonc.2021.637420
Novel therapeutics in myeloproliferative neoplasms.
Venugopal S, Mascarenhas J. · · 2020 · cited 32× · PMID 33267911 · DOI 10.1186/s13045-020-00995-y
High frequencies of circulating memory T cells specific for calreticulin exon 9 mutations in healthy individuals.
Holmström MO, Ahmad SM, Klausen U, Bendtsen SK, et al · · 2019 · cited 30× · PMID 30655510 · DOI 10.1038/s41408-018-0166-4
Inflammatory Microenvironment and Specific T Cells in Myeloproliferative Neoplasms: Immunopathogenesis and Novel Immunotherapies.
Nasillo V, Riva G, Paolini A, Forghieri F, et al · · 2021 · cited 28× · PMID 33672997 · DOI 10.3390/ijms22041906
Cancer Immune Therapy for Philadelphia Chromosome-Negative Chronic Myeloproliferative Neoplasms.
Holmström MO, Hasselbalch HC, Andersen MH. · · 2020 · cited 22× · PMID 32630667 · DOI 10.3390/cancers12071763
PD-1/PD-L1, MDSC Pathways, and Checkpoint Inhibitor Therapy in <i>Ph</i>(-) Myeloproliferative Neoplasm: A Review.
Wang JC, Sun L. · · 2022 · cited 18× · PMID 35628647 · DOI 10.3390/ijms23105837

Verify or expand the search:

Other recruiting trials for Myeloproliferative Neoplasm, Unclassifiable

Currently open trials in the same condition.

NCT07362225 — MPN PROGRESSion Registry: Observational Study Tracking Symptoms, Treatments, and Disease Progression in People With Myel · recruiting
NCT03862157 — Azacitidine, Venetoclax, and Pevonedistat in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia · Phase 1, PHASE2 · active not recruiting

Other Inge Marie Svane trials

Trials by the same sponsor.

NCT07501117 — Neoadjuvant Immunotherapy for Patients With High-risk Eye Melanoma · Phase 1 · not yet recruiting
NCT06204991 — To Evaluate the Safety and Efficacy of ADP-TILIL7 in Patients With Locally Advanced or Metastatic Melanoma · Phase 1 · recruiting
NCT06783270 — T-cell Therapy with CRISPR PD1-edited Tumor Infiltrating Lymphocytes for Patients with Metastatic Melanoma · Phase 1 · recruiting
NCT04904185 — ImmPACT Expanded Multiple Antigen Specific Endogenously Derived T Cells (MASE-T) to Patients With Metastatic Melanoma · Phase 1 · terminated
NCT04611126 — T-cell Therapy in Combination With Nivolumab, Relatlimab and Ipilimumab for Patients With Metastatic Ovarian Cancer · Phase 1, PHASE2 · terminated

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT03566446 (US National Library of Medicine, public domain)
Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Inge Marie Svane
Last refreshed: 13 July 2023

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT03566446.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing